Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 12, 2023
Deals
Seeking high-value drugs, Novartis adds kidney franchise in $3.2B Chinook takeout
Biotech’s later-stage candidates give pharma two chances at a blockbuster, starting with IgA nephropathy indication amid rising competition
BioCentury | Apr 11, 2023
Finance
April 11 Quick Takes: VintaBio debuts with $64M to tackle viral vector bottleneck
Plus: Moderna forecasts up to $15B in 2027 sales of respiratory franchise and updates from HI-Bio, Chinook, Impact-Junshi and more
BioCentury | Nov 18, 2021
Deals
Eyeing RNAi platform more than pipeline, Novo buys Dicerna for $3.3B
Building on prior deal around hepatic platform, takeout gives Novo broader access to Dicerna’s technology
Items per page:
1 - 10 of 15